SCHEMBL3220656

SCHEMBL3220656

NC(=O)n1cc(Br)c(=O)[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
SQOR Q9Y6N5 1/20 0.53
ASAH1 Q13510 1/20 0.49
GRIA1 P42261 1/20 0.47
GRIA2 P42262 1/20 0.47
GRIA4 P48058 1/20 0.47
GRIK5 Q16478 1/20 0.47
GAA P10253 1/20 0.40
KMT2A Q03164 2/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DTYMK P23919 1/20 0.37
PYGM P11217 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15537870 0.82 SQOR (0.54) TDP1SQORASAH1GRIA1GRIA2
SCHEMBL7540032 0.77 LMNA (0.49) SQORASAH1GRIA1GRIA2GRIA4
SCHEMBL16034683 0.76 DDO (0.42) GRIA1GRIA2GRIA4GRIK5GAA
SCHEMBL8235112 0.73 SQOR (0.49) TDP1SQORASAH1GRIA1GRIA2
SCHEMBL400005 0.71 TDP1 (1.00) TDP1SQORASAH1GRIA1GRIA2
SCHEMBL28179393 0.71 TDP1 (0.57) TDP1SQORGRIA1GRIA2GRIA4
SCHEMBL19147850 0.70 SQOR (1.00) TDP1SQORASAH1GAAKMT2A
SCHEMBL5117415 0.68 GRIA1 (0.54) TDP1SQORGRIA1GRIA2GRIA4
SCHEMBL22114444 0.67 TDP1 (0.57) TDP1SQORASAH1GRIA1GRIA2
SCHEMBL35345 0.67 TDP1 (0.57) TDP1SQORASAH1GRIA1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 TDP1 1722/4885SQOR 666/4885ASAH1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.